Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S, Ferrozzi F, Giardini R, Bertoni R, Turley H, Gatter K, Petronini PG, Fox SB, Harris AL, Martinotti M, Berruti A, Bottini A, Reynolds AR, Generali D.
Bazzola L, et al. Among authors: andreis d.
Br J Cancer. 2015 Jan 6;112(1):52-60. doi: 10.1038/bjc.2014.563. Epub 2014 Dec 2.
Br J Cancer. 2015.
PMID: 25461806
Free PMC article.